ASMB - Assembly Biosciences, Inc. EV/EBITDA Multiple

assemblybio.com (ASMB) - corporate logo

The available price action vector for Assembly Biosciences (ASMB) based on the EV/EBITDA metric is 0.00, while the ASMB business does not generate stable income due to a lack of commercialized products. Current capital is being depleted by biopharmaceutical expenditures, which are partially offset by bonuses from global partners. The company relies on a secured test delivery system that minimizes the risk of disruptions in the development of hepatitis treatments.

ASMB (Assembly Bio) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for assemblybio.com (ASMB)

- market price and analyst price targets:
Price Chart Assembly Biosciences Inc|ASMB - Price Target Chart
- market capitalization statistics:
Market Capitalization Assembly Corp|ASMB - Company Buyout Price
- issuer book value statistics:
Accounting Value per Share Assembly Biosciences|ASMB - Company Book Value|Market Capitalization to Book Value Ratio assemblybio.com|ASMB - Company Assets
- company liabilities and liquidity data:
Debt to Equity Assembly Biosciences|ASMB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Assembly Biosciences, Inc.|ASMB - Company Aggregate Debts|Debt to Book Capitalization Ratio Assembly Corp|ASMB - Long-Term Debt Volume|Company Short-Term Debt Assembly Biosciences|Quick Ratio assemblybio.com
- net income and valuation multiples indicators:
ASMB - Company Net Income|Expected Profit Assembly Biosciences|ASMB - Price to Earnings Ratio|Forward P/E Multiple Assembly Biosciences|ASMB - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assembly Corp|ASMB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Assembly Biosciences|ASMB - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months assemblybio.com|ASMB - Earnings per share increase in current year|Earnings growth forecast for next year Assembly Biosciences
Fundamental company analysis:ASMB (Assembly Biosciences Inc)
Original product of assemblybio.com

The multiple correlates the total enterprise value, including debt, with operating profit before depreciation and amortization and taxes. This metric determines the real value of capital-intensive assets by excluding the impact of accounting policies and debt load. For Assembly Biosciences (ASMB), this reflects resource efficiency amid the targeted hiring of niche pharmacology specialists. By analyzing the historical EV/EBITDA chart for Assembly Biosciences (ASMB), an investor can identify the capital consolidation phase preceding a new price impulse.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arrowhead Pharmaceuticals Inc ARWR|Mirum Pharmaceuticals Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Dynavax Technologies Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio arbutusbio.com ABUS|IVA (Inventiva) - Enterprise Value to EBITDA Ratio|GYRE (Gyre Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GALT (Galectin Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Genfit Corp GNFT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DURECT Corporation (DRRX)|ALGS (aligos.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BIVI (BioVie)|EV/EBITDA Multiple Galmed Pharmaceuticals Ltd GLMD|NDRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Hepion Pharmaceuticals HEPA